Print Clear

Prior Authorization Request Administrative Information

Member Information

Last name _____ First name _____ MI _____

Member ID _____ Date of birth _____

Sex assigned at birth ☐ Female ☐ Male ☐ "X" or Intersex

Current gender ☐ Female ☐ Male ☐ Transgender male ☐ Transgender female ☐ Other _____

Place of residence ☐ Home ☐ Nursing facility ☐ Other _____

Race/ethnicity _____ Preferred spoken language _____ Preferred written language _____

MassHealth does not exclude people or treat them differently because of race, color, national origin, age, disability, religion, creed, sexual orientation, or sex (including gender identity and gender stereotyping).

Plan Contact Information

Please indicate the member's MassHealth Plan and fax or submit this completed and signed form according to the Plan's contact information below.

MassHealth Fee-For-Service (FFS) Plan, Primary Care Clinician (PCC) Plan, Primary Care Accountable Care Organization (PCACO) Plan, Children's Medical Security Plan, and Health Safety Net Plan
☐ **MassHealth Drug Utilization Review Program** Pharmacy: Fax: (877) 208-7428 - Tel: (800) 745-7318
MassHealth Managed Care Organization (MCO) and Accountable Care Partnership Plans (ACPP)
☐ **Fallon Health** Online Prior Authorization: go.covermymeds.com/OptumRx Online Prior Authorization: providerportal.surescripts.net/ProviderPortal/optum Pharmacy: Fax: (844) 403-1029 - Tel: (844) 720-0033
☐ **Health New England** Online Prior Authorization: go.covermymeds.com/OptumRx Pharmacy: Fax: (800) 550-9246 - Tel: (800) 918-7545
☐ **Mass General Brigham Health Plan** Online Prior Authorization (Non-Specialty Drugs): go.covermymeds.com/OptumRx Online Prior Authorization (Specialty/Medical Drugs): provider.massgeneralbrighamhealthplan.org Pharmacy: Fax: (844) 403-1029 - Tel: (800) 711-4555
☐ **Tufts Health Plan** Online Prior Authorization: point32health.promptpa.com Pharmacy: Fax: (617) 673-0939 - Tel: (888) 257-1985
☐ **WellSense Health Plan** Online Prior Authorization: wellsense.org/providers/ma/pharmacy/prior-authorizations Pharmacy: Fax: (833) 951-1680 - Tel: (877) 417-1822

over

Glaucoma Agents
Prior Authorization Request

MassHealth reviews requests for prior authorization (PA) on the basis of medical necessity only. If MassHealth approves the request, payment is still subject to all general conditions of MassHealth, including current member eligibility, other insurance, and program restrictions. MassHealth will notify the requesting provider and member of its decision. Keep a copy of this form for your records. If faxing this form, please use black ink.

Additional information about these agents, including PA requirements and preferred products, can be found within the MassHealth Drug List at **www.mass.gov/druglist.**

Medication information

Medication requested

- ☐ Betimol (timolol)
- ☐ bimatoprost 0.03% ophthalmic solution
- ☐ brimonidine/timolol, ophthalmic
- ☐ dorzolamide/timolol preservative free
- ☐ Durysta (bimatoprost implant) [MB]
- ☐ Iyuzeh (latanoprost solution)
- ☐ Rhopressa (netarsudil)
- ☐ Rocklatan (netarsudil/latanoprost)
- ☐ tafluprost
- ☐ timolol ophthalmic gel forming solution
- ☐ timolol ophthalmic unit dose solution
- ☐ Vyzulta (latanoprostene)
- ☐ Xelpros (latanoprost emulsion)

[MB] *This drug is available through the health care professional who administers the drug or in an outpatient or inpatient hospital setting. MassHealth does not pay for this drug to be dispensed through the retail pharmacy. If listed, prior authorization does not apply through the hospital outpatient and inpatient settings. Please refer to 130 CMR 433.408 for prior authorization requirements for other health care professionals. Notwithstanding the above, this drug may be an exception to the unified pharmacy policy; please refer to respective MassHealth Accountable Care Partnership Plans (ACPPs) and Managed Care Organizations (MCOs) for prior authorization status and criteria, if applicable.*

Indication (Check all that apply or include ICD-10 code, if applicable.)

☐ Open-angle glaucoma ☐ Ocular hypertension ☐ Other

Dose, frequency, and duration of medication requested

Drug NDC (if known) or service code

Section I. Please complete for Betimol, timolol ophthalmic gel forming solution and timolol ophthalmic unit dose solution requests.

Has the member had a trial with an ophthalmic timolol formulation that is available without PA?

☐ Yes ☐ No. Please provide clinical rationale for not using an ophthalmic timolol formulation that is available without PA.

Section II. Please complete for bimatoprost 0.03% requests.

Has the member had a trial with latanoprost solution or travoprost 0.004% eye drop?

☐ Yes. Please list the drug name, dates/duration of use, and outcomes below.

Drug name Dates/duration

Did the member experience any of the following? ☐ Adverse reaction ☐ Inadequate response ☐ Other

Briefly describe details of adverse reaction, inadequate response, or other.

Drug name Dates/duration

Did the member experience any of the following? ☐ Adverse reaction ☐ Inadequate response ☐ Other

Briefly describe details of adverse reaction, inadequate response, or other.

☐ No. Please provide clinical rationale for not using latanoprost solution and travoprost 0.004% eye drops.

Section III. Please complete for Durysta requests.

1. Has the member had a trial with Lumigan?
   ☐ Yes. Please list the dates/duration of use and outcomes below.

   Dates/duration ☐ Adverse reaction ☐ Inadequate response ☐ Other

   Briefly describe details of adverse reaction, inadequate response, or other.

   ☐ No. Please describe medical necessity for an implantable formulation instead of eye drops.
2. Please specify affected eye. ☐ Left eye ☐ Right eye
3. Is the request for retreatment of the same eye? ☐ Yes ☐ No

Section IV. Please complete for dorzolamide/timolol preservative free and Xelpros requests.

Has the member experienced sensitivity to benzalkonium chloride or any other preservatives used in ophthalmic preparations?

☐ Yes ☐ No. Please provide clinical rationale for the use of the requested formulation instead of the respective formulation that is available without PA.

Section V. Please complete for brimonidine/timolol, ophthalmic requests.

Has the member had a trial with dorzolamide/timolol?

☐ Yes. Please list the dates/duration of use and outcomes below.

Dates/duration ☐ Adverse reaction ☐ Inadequate response ☐ Other

Briefly describe details of adverse reaction, inadequate response, or other.

☐ No. Please provide clinical rationale for not using dorzolamide/timolol.

Section VI. Please complete for Rhopressa and Rocklatan requests.

1. Has the member had a trial of combination therapy with a prostaglandin analog and an ophthalmic beta-blocker?
   ☐ Yes. Please list the drug names, dates/duration of use and outcomes below.*
   ☐ No. Please provide clinical rationale for not using combination therapy with a prostaglandin analog and an ophthalmic beta-blocker.
2. Does the member have a contraindication to ophthalmic beta-blockers?
   ☐ Yes. Please describe. ☐ No

   If yes, has the member had a trial of combination therapy with a prostaglandin analog and either an ophthalmic alpha-2 adrenergic agonist, parasympathomimetic, or carbonic anhydrase inhibitor?

over

☐ Yes. Please list the drug names, dates/duration of use and outcomes below.* ☐ No

3. For Rhopressa, does the member have a contraindication to prostaglandin analogs?

☐ Yes. Please describe. ☐ No

If yes, has the member had a trial of combination therapy with an ophthalmic beta-blocker and either an ophthalmic alpha-2 adrenergic agonist, parasympathomimetic, or carbonic anhydrase inhibitor?

☐ Yes. Please list the drug names, dates/duration of use and outcomes below.* ☐ No

Please provide details for the previous trials.

Drug Dates/duration ☐ Adverse reaction ☐ Inadequate response ☐ Other

Briefly describe details of adverse reaction, inadequate response, or other.

Drug Dates/duration ☐ Adverse reaction ☐ Inadequate response ☐ Other

Briefly describe details of adverse reaction, inadequate response, or other.

**Please attach a letter documenting additional trials as necessary.*

Section VII. Please complete for Vyzulta requests.

Has the member had an inadequate response to a trial of combination therapy with latanoprost solution and an ophthalmic beta-blocker? ☐ Yes ☐ No.

If no, has the member had a trial with latanoprost solution?

☐ Yes. Please list the dates/duration of use and outcomes below.

Dates/duration Outcome

If no, has the member had an adverse reaction to an ophthalmic beta-blocker?

☐ Yes. Please list the dates/duration of use and outcomes below.

Dates/duration Outcome

☐ No. Please provide clinical rationale for not using ophthalmic beta-blocker.

Section VIII. Please complete for Iyuzeh and tafluprost requests.

1. Has the member had a trial with latanoprost solution available without PA?

☐ Yes. Please list the dates/duration of use and outcomes below.

Dates/duration ☐ Adverse reaction ☐ Inadequate response ☐ Other

Briefly describe details of adverse reaction, inadequate response, or other.

☐ No. Please provide clinical rationale for not using latanoprost solution available without PA.

2. Has the member had a trial with Xelpros?

☐ Yes. Please list the dates/duration of use and outcomes below.

Dates/duration ☐ Adverse reaction ☐ Inadequate response ☐ Other

Briefly describe details of adverse reaction, inadequate response, or other.

☐ No. Please provide clinical rationale for not using Xelpros.

over

Section IX. Please complete and provide documentation for exceptions to Step Therapy.

1. Is the alternative drug required under the step therapy protocol contraindicated, or will likely cause an adverse reaction in, or physical or mental harm to the member? ☐ Yes ☐ No
   If yes, briefly describe details of contraindication, adverse reaction, or harm.

2. Is the alternative drug required under the step therapy protocol expected to be ineffective based on the known clinical characteristics of the member and the known characteristics of the alternative drug regimen?
   ☐ Yes ☐ No
   If yes, briefly describe details of known clinical characteristics of member and alternative drug regimen.

3. Has the member previously tried the alternative drug required under the step therapy protocol, or another alternative drug in the same pharmacologic class or with the same mechanism of action, and such alternative drug was discontinued due to lack of efficacy or effectiveness, diminished effect, or an adverse event? ☐ Yes ☐ No
   If yes, please provide details for the previous trial.
   Drug name Dates/duration of use
   Did the member experience any of the following? ☐ Adverse reaction ☐ Inadequate response
   Briefly describe details of adverse reaction or inadequate response.

4. Is the member stable on the requested prescription drug prescribed by the health care provider, and switching drugs will likely cause an adverse reaction in or physical or mental harm to the member?
   ☐ Yes. Please provide details.
   ☐ No

Please continue to next page and complete Prescriber and Provider Information section.

Prior Authorization Request Prescriber and Provider Information

Prescriber Information

Last name* First name* MI

NPI* Individual MH Provider ID

DEA No. Office Contact Name

Address City State Zip

Email address

Telephone No.* Fax No.*

** Required*

Please also complete for professionally administered medications, if applicable.

Start date End date

Servicing prescriber/facility name ☐ Same as prescribing provider

Servicing provider/facility address

Servicing provider NPI/tax ID No.

Name of billing provider

Billing provider NPI No.

Is this a request for recertification? ☐ Yes ☐ No

CPT code No. of visits J code No. of units

Prescribing provider's attestation, signature, and date

I certify under the pains and penalties of perjury that I am the prescribing provider identified in the Prescriber information section of this form. Any attached statement on my letterhead has been reviewed and signed by me. I certify that the medical necessity information (per 130 CMR 450.204) on this form is true, accurate, and complete, to the best of my knowledge. I understand that I may be subject to civil penalties or criminal prosecution for any falsification, omission, or concealment of any material fact contained herein.

Prescribing provider's signature _____

Printed name of prescribing provider Date

(The form can either be signed by hand and then scanned, or it can be signed electronically using DocuSign or Adobe Sign. For electronic signatures, the signer can upload a picture of their wet signature. The typed text of a signature is not an acceptable form of an electronic signature.)